Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Open Label Study to Evaluate Cholesterol Efflux Mediator VAR200: 2- Hydroxypropyl-β-cyclodextrin (2-HPβCD) in Subjects with Type 2 Diabetic Kidney Disease (DKD)

Next Previous
Trial Profile

A Phase 2a Open Label Study to Evaluate Cholesterol Efflux Mediator VAR200: 2- Hydroxypropyl-β-cyclodextrin (2-HPβCD) in Subjects with Type 2 Diabetic Kidney Disease (DKD)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 May 2025 According to ZyVersa Therapeutics media release, First patient expected to start therapy by end of Q2-2025 (around the end of June/early July ) in this Phase 2a proof-of concept clinical trial.
  • 27 Mar 2025 According to ZyVersa Therapeutics media release, this phase 2a clinical trial in patients with DKD is expected to begin in the first half of 2025
  • 24 Jan 2025 Planned End Date changed from 11 Jul 2025 to 1 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top